Kisspeptin-10
Kisspeptin-10 is a synthetic decapeptide fragment of kisspeptin studied as a tool for probing the hypothalamic-pituitary-gonadal axis and gonadotropin (LH/FSH) release; research protocols typically use 125 mcg daily subcutaneously.
Best for
It has been studied as a research tool for probing the hypothalamic-pituitary-gonadal axis, including reproductive and hormonal signaling, gonadotropin (LH/FSH) release, and libido-related research.
What to expect
Research using intravenous bolus dosing reported a rapid, dose-dependent rise in serum LH, with peak LH concentrations observed around 30 minutes after administration.
Pairs with
In HPG-axis and reproductive research it is sometimes examined alongside or compared with longer-acting kisspeptin-54 and against GnRH, and discussed in the context of fertility-focused protocols rather than as a fixed stack.
In published human research it has most often been administered intravenously as a bolus or continuous infusion (e.g., bolus doses on the order of ~1 microgram/kg, or infusions of ~1.5-4 micrograms/kg per hour) to study acute LH responses, and dosing in non-clinical research settings is not standardized.
- How often
- Daily
- When
- Bedtime
- Route
- Subcutaneous
- Vial & water
- 10 mg vial in 3 mL = 3.33 mg/mL · 125 mcg = 3.75 units on a U-100 syringe
- Cycle
- 30 days on, 30 days off
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
Kisspeptin-10 (KP-10) is a synthetic decapeptide corresponding to the conserved C-terminal fragment (residues 112-121) of kisspeptin-54/metastin, the neuropeptide encoded by the KISS1 gene. It is the minimal sequence required for receptor activation.
Kisspeptin-10 is not FDA-approved; it is handled as a research compound, and related kisspeptin analogs remain investigational.
Research has characterized it as a potent agonist of the kisspeptin receptor KISS1R (also known as GPR54), a G-protein-coupled receptor expressed on hypothalamic GnRH neurons. Binding has been studied as an upstream trigger of gonadotropin-releasing hormone (GnRH) secretion, which in turn has been associated with downstream release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, positioning kisspeptin as a key regulator of the hypothalamic-pituitary-gonadal (HPG) axis.
Human studies have reported dose-dependent increases in serum LH and changes in LH pulse frequency following intravenous administration.
- Half-life
- Very short; reported on the order of a few minutes in plasma (shorter than kisspeptin-54)
- Peak
- ~30 min to peak LH after IV bolus (research)
- Absorption
- Studied via IV administration (bolus/infusion) in human research
- Bioavailability
- Not well characterized for non-IV routes; oral bioavailability expected to be negligible (peptide)
References3
- George JT et al. - Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (J Clin Endocrinol Metab)
- Jayasena CN et al. - The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans (J Clin Endocrinol Metab)
- PubChem - Kisspeptin-10 Compound Summary, CID 25240297 (sequence, C63H83N17O14, MW 1,302.4)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.